AXS-14 (esreboxetine) is a novel, oral, investigational medicine. It is a highly selective and potent norepinephrine reuptake inhibitor.
Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.
AXS-14 has met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and in a Phase 2 trial for the treatment of fibromyalgia.
AXS-14 is an investigational drug not approved by the FDA and its safety and effectiveness have not been established.
clinical and regulatory
AXS-14 is currently being developed for the treatment of fibromyalgia. The product is in the preparing to submit an NDA phase of development.
